- Home
- BCTX vs LPTX Comparison
BCTX vs LPTX Comparison
Compare BCTX & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- LPTX
- Stock Information
- Founded
- BCTX 2014
- LPTX 2011
- Country
- BCTX Canada
- LPTX United States
- Employees
- BCTX N/A
- LPTX N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCTX Health Care
- LPTX Health Care
- Exchange
- BCTX Nasdaq
- LPTX Nasdaq
- Market Cap
- BCTX 13.7M
- LPTX 14.7M
- IPO Year
- BCTX N/A
- LPTX N/A
- Fundamental
- Price
- BCTX $0.81
- LPTX $0.36
- Analyst Decision
- BCTX Strong Buy
- LPTX Hold
- Analyst Count
- BCTX 1
- LPTX 1
- Target Price
- BCTX $32.00
- LPTX N/A
- AVG Volume (30 Days)
- BCTX 2.5M
- LPTX 661.7K
- Earning Date
- BCTX 06-16-2025
- LPTX 08-11-2025
- Dividend Yield
- BCTX N/A
- LPTX N/A
- EPS Growth
- BCTX N/A
- LPTX N/A
- EPS
- BCTX N/A
- LPTX N/A
- Revenue
- BCTX N/A
- LPTX N/A
- Revenue This Year
- BCTX N/A
- LPTX N/A
- Revenue Next Year
- BCTX N/A
- LPTX N/A
- P/E Ratio
- BCTX N/A
- LPTX N/A
- Revenue Growth
- BCTX N/A
- LPTX N/A
- 52 Week Low
- BCTX $0.69
- LPTX $0.22
- 52 Week High
- BCTX $29.40
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- BCTX 14.56
- LPTX 51.90
- Support Level
- BCTX $0.69
- LPTX $0.33
- Resistance Level
- BCTX $3.00
- LPTX $0.36
- Average True Range (ATR)
- BCTX 0.20
- LPTX 0.03
- MACD
- BCTX -0.15
- LPTX 0.01
- Stochastic Oscillator
- BCTX 4.75
- LPTX 81.25
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.